Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. - Timofeeva N; Herrera B; Fujiwara H; Asami T; Endo H; Hatakeyama M; Nakajima F; Ohmoto H; Nishioka Y; Miyamoto K; Arimura A; Tantawy SI; et al. (Blood cancer journal, 2026)